A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : JMML / juvenile myelomonocytic leukemia

[Related PubMed/MEDLINE]
Total Number of Papers: 383
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   JMML  (>> Co-occurring Abbreviation)
Long Form:   juvenile myelomonocytic leukemia
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out. circRNAs, HD, miRNA
2021 Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia. HSPCs, LSCs
2021 Juvenile myelomonocytic leukemia presenting in an infant with a subdural hematoma. ---
2021 Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia. lncRNAs
2021 Pediatric Neoplasms Presenting with Monocytosis. ---
2021 Stem cell origins of JMML. ---
2021 Treatment advances for pediatric and adult onset neoplasms with monocytosis. CMML, HMAs, MDS
2020 A child with juvenile myelomonocytic leukemia possessing a concurrent germline CBL mutation and a NF1 variant of uncertain significance: A rare case with a common problem in the era of high-throughput sequencing. ---
2020 After 95 years, it's time to eRASe JMML. ---
10  2020 B-lymphocyte deficiency and recurrent respiratory infections in a 6-month-old female infant with mosaic monosomy 7. FISH, MDS, PID
11  2020 CD14/16 monocyte profiling in juvenile myelomonocytic leukemia. ---
12  2020 Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report. HSCT
13  2020 Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors. LS, NS, PTP, SHP2
14  2020 Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. aCML, CMML, MDS, MDS-RS, MPN
15  2020 Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease. MFC, NF1, PTPN11
16  2020 International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia. HM, OS
17  2020 Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. pCMML
18  2020 Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. ---
19  2020 Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. aCML, CMML, MDS, MPN
20  2020 Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine. HSCT, TLC
21  2020 Parvovirus B19 Infection Mimicking Juvenile Myelomonocytic Leukemia in an Immunocompetent Child. FUO
22  2020 Primary Graft Failure but Treatment Success: A Case of Reversion to Heterozygosity After Allogeneic Hematopoietic Cell Transplantation With Autologous Hematopoietic Recovery in a Child With CBL-related Juvenile Myelomonocytic Leukemia. ---
23  2020 Prolonged Pediatric Extracorporeal Membrane Oxygenation Support with Cardiopulmonary Failure in Juvenile Myelomonocytic Leukemia. ECMO
24  2020 RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience. ---
25  2020 Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia. ---
26  2020 Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation. MD
27  2020 Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia. AZA, cPR, cSD, gSD, HMA, HSCT, i.v, NGS
28  2020 [Analysis of Gene Mutation and Clinical Characteristics in 19 Children with Juvenile Myelomonocytic Leukemia]. HSCT
29  2020 [Efficacy Analysis of Unrelated Cord Blood Transplantation in the Treatment of Juvenile Myelomonocytic Leukemia]. CsA, MMF, UCBT
30  2019 Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation. GVHD, HR, HSCT, OS
31  2019 Concurrent juvenile myelomonocytic leukemia with thalassemia in a case with Plasmodium knowlesi infection from Sabah, Malaysian Borneo. CMML
32  2019 Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. JMML-PCs
33  2019 Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches. AZA, HSCT
34  2019 Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches. AZA, HSCT
35  2019 Diagnosis and treatment of juvenile myelomonocytic leukemia. DFS, HSCT, OS
36  2019 Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia. iPSC
37  2019 Gain-of-Function SHP2 E76Q Mutant Rescuing Autoinhibition Mechanism Associated with Juvenile Myelomonocytic Leukemia. PTP
38  2019 Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia. ---
39  2019 Juvenile myelomonocytic leukemia: who's the driver at the wheel? ---
40  2019 Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. HCT
41  2019 Persistence of HIV reservoir following successful haematopoietic stem cell transplant for juvenile myelomonocytic leukaemia in a child with perinatally acquired HIV. ---
42  2019 Precision cancer monitoring using a novel, fully integrated, microfluidic array partitioning digital PCR platform. cfDNA, CML, dPCR, NSCLC
43  2019 Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia. ---
44  2019 PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center. EFS
45  2019 Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia. RGS
46  2019 Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia. HSCT
47  2019 [Clinical and genetic analyses of juvenile myelomonocytic leukemia]. ---
48  2018 Adrenal crisis in a 14-year-old boy 12 years after hematopoietic stem cell transplantation. APS, HSCT
49  2018 Cutaneous involvement in an 8-year-old boy with Ras-associated autoimmune leucoproliferative disorder (RALD). BM, RALD
50  2018 Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Bu-Cy-Mel, Bu-Flu, HCT
51  2018 Exploring the effect of E76K mutation on SHP2 cause gain-of-function activity by a molecular dynamics study. SHP2
52  2018 Gene module analysis of juvenile myelomonocytic leukemia and screening of anticancer drugs. GO, KEGG
53  2018 Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL. ---
54  2018 Hematopoietic-restricted Ptpn11E76K reveals indolent MPN progression in mice. MPN
55  2018 Integrated molecular profiling of juvenile myelomonocytic leukemia. AML
56  2018 JMML genomics and decisions. ---
57  2018 Juvenile myelomonocytic leukemia with t(3;5)(q25;q35), Auer rods and marked myelodysplasia. ---
58  2018 KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia. AML, KMT2A, MLL
59  2018 Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. iPSCs
60  2018 Panobinostat inhibits the proliferation of CD34+ CD38- cells under stimulation of hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia. ---
61  2018 Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. WAS
62  2018 Sphenoidal sinogenic extradural empyema associated with juvenile myelomonocytic leukemia. MMS
63  2018 Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia. AML, MAPK
64  2018 USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism. AML, CMML, USP22
65  2018 [Advances in the treatment of juvenile myelomonocytic leukemia]. ---
66  2018 [Clinical and laboratory characteristics of juvenile myelomonocytic leukemia]. ChE, CML, MDS
67  2018 [Progress in research of the pathogenesis of childhood MDS/MPN]. MDS
68  2017 A case of splenomegaly in CBL syndrome. WES
69  2017 Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. CMML
70  2017 Association Between Juvenile Myelomonocytic Leukemia, Juvenile Xanthogranulomas and Neurofibromatosis Type 1: Case Report and Review of the Literature. JXG, NF1
71  2017 Blastic transformation of juvenile myelomonocytic leukemia caused by the copy number gain of oncogenic KRAS. ---
72  2017 Complete Resolution of Lymphoid Interstitial Pneumonia in a Patient With Juvenile Myelomonocytic Leukemia Treated With Allogeneic Bone Marrow Transplant: Killing 2 Birds With 1 Stone. ASXL1, LIP, PTPN11
73  2017 De novo mutations in CBL causing early-onset paediatric moyamoya angiopathy. MMA, WES
74  2017 DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. HSCT, MDS
75  2017 Epigenetic dysregulation of the erythropoietic transcription factor KLF1 and the beta-like globin locus in juvenile myelomonocytic leukemia. ---
76  2017 Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. ---
77  2017 Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of Sixty-five Patients. HSCT
78  2017 Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome. ---
79  2017 Mice expressing KrasG12D in hematopoietic multipotent progenitor cells develop neonatal myeloid leukemia. ---
80  2017 Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. ---
81  2017 RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. HM, IM
82  2017 Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. BM, CMML, GM-CSF, MDS, MPN
83  2017 SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome. aCML, CMML, MDS, MPN
84  2017 Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7. ---
85  2017 Unexpected Findings in a Child with Atypical Hemolytic Uremic Syndrome: An Example of How Genomics Is Changing the Clinical Diagnostic Paradigm. ---
86  2017 Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report. GVL, HSCT
87  2017 Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients. ---
88  2017 Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice. GM-CSF, MPN, YS EMPs
89  2017 [Clinical Study on Treatment of Juvenile Myelomonocytic Leukemia with Haploidentical-Hematopoietic Stem Cell Transplantation]. GVHD, hi-HSCT
90  2017 [Multiple granular cell tumours in a patient with Noonan's syndrome and juvenile myelomonocytic leukaemia]. GCT
91  2016 A 27-Year-Old Patient Fulfilling the Diagnostic Criteria of Both CMML and JMML. CMML
92  2016 Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia. AMS, OS, TFS
93  2016 Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy. HSCT
94  2016 An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. aCML, CMML, MDS/MPN, RARS-T, WHO
95  2016 Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia. CAR, GM-CSF
96  2016 Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. BM, CTRLs, MDS, RAEB, RAEB-t, RCC
97  2016 Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. aCML, CMML, RARS-T
98  2016 CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia. CREBBP
99  2016 Diagnosis and treatment of juvenile myelomonocytic leukemia. HSCT
100  2016 Early T-Cell Precursor Acute Lymphoblastic Leukemia in an Infant With an NRAS Q61R Mutation and Clinical Features of Juvenile Myelomonocytic Leukemia. ETP-ALL, T-ALL